When Diabetes Technology Damages the Skin: Keeping Patients on CGMs and Insulin Pumps

Continuous glucose monitors (CGMs) and insulin pumps can transform diabetes management, but the technology only works when patients can comfortably keep wearing it. CGM skin irritation can turn a valuable device into a daily source of itching, redness, pain, or damaged skin. In some cases, the reaction becomes severe enough that a patient stops using the device altogether. Current diabetes guidance therefore treats skin reactions as a practical barrier that clinicians should actively assess and address.

For healthcare professionals, prevention should start before the first patch of irritated skin appears. Thoughtful site selection, skin preparation, adhesive management, and early recognition of dermatitis can help patients continue benefiting from diabetes technology.

Table of Contents

• Why CGM skin irritation develops
• Preparing skin before device placement
• Barrier films and adhesive strategies
• Managing reactions before patients discontinue devices
• Conclusion
• Frequently asked questions

Why CGM Skin Irritation Develops

Not every red patch under a sensor or pump is an adhesive allergy. Irritant contact dermatitis and allergic contact dermatitis can look similar, yet they arise through different mechanisms. Irritant dermatitis results from direct damage to the skin barrier. Sweat, friction, moisture trapped beneath a device, repeated adhesive removal, and other physical or chemical irritation can contribute.

Allergic contact dermatitis, in contrast, is an immune-mediated reaction following sensitization to a particular substance. Acrylates and other components associated with diabetes devices have been implicated in reported reactions. Isobornyl acrylate, or IBOA, became one of the best-known examples, although device formulations can change over time.

Consequently, clinicians should avoid assuming that every CGM-related skin reaction has the same cause. Ask patients about itching, burning, blistering, drainage, pain, and how quickly symptoms develop. Also inspect the distribution of the rash relative to the adhesive and device housing.

Skin history matters as well. Patients with existing barrier problems, including atopic dermatitis, may be more vulnerable to irritation or sensitization.

Most importantly, ask about skin symptoms during routine diabetes visits rather than waiting for patients to complain. The American Diabetes Association Standards of Care recommends periodically asking CGM users about adhesive reactions.

Prevent CGM Skin Irritation Before Device Placement

Prevention begins with choosing healthy skin. Whenever possible, patients should avoid applying a sensor or infusion set over active dermatitis, cuts, scars, irritated areas, or recently used sites.

Site rotation is equally important. Repeatedly exposing one area to adhesive, insertion trauma, and removal can prevent the skin from fully recovering. For pump users, repeated use of the same region can also contribute to lipohypertrophy, which may make insulin absorption less predictable.

Before application, the site should be clean and completely dry. However, more cleaning is not necessarily better. Patients who react to a device may also react to auxiliary products used around it. For example, some cleansing or adhesive-removal products contain potential sensitizers.

Therefore, review the patient’s entire application routine when irritation occurs. That includes wipes, soaps, skin-preparation products, overpatches, adhesive removers, and anything else touching the site.

Hair can also interfere with adhesion and create pulling or friction. When needed, carefully clipping hair may be preferable to aggressive shaving immediately before application because shaving can produce small areas of barrier injury.

Finally, allow any manufacturer-approved preparation product to dry completely before attaching the device. Clinicians should also review the specific manufacturer’s instructions because application requirements vary between CGMs, infusion sets, and automated insulin delivery systems.

Barrier Films and Adhesive Strategies for Sensitive Skin

Barrier products are commonly considered when patients experience recurring skin irritation from CGM use. A barrier film creates a thin layer between the skin and adhesive and may reduce direct exposure or friction for some patients.

However, barrier products are not a universal solution. Published research suggests that barrier films may provide benefit to only some affected patients. Therefore, clinicians should set realistic expectations rather than presenting barrier films as guaranteed prevention.

The practical question is also whether a particular barrier technique is compatible with the patient’s device. Patients should follow manufacturer instructions because placing unapproved materials beneath a sensor or infusion set could potentially affect adhesion, insertion, wear, or performance.

Overpatches and supplemental adhesives present another balancing act. They may help keep a device secure during exercise, sweating, or water exposure. However, adding more adhesive increases the amount of material contacting the skin. If irritation develops beneath the supplemental product, adding another layer may make the problem worse.

Removal technique deserves similar attention. Pulling an adhesive quickly from dry skin can strip the outer skin barrier. Instead, patients should follow the device manufacturer’s removal instructions and use compatible adhesive-removal products when appropriate.

After removal, clinicians can encourage patients to inspect the site. Persistent redness, scaling, swelling, blistering, or broken skin deserves attention before another device is placed in the same location.

Manage Skin Reactions Before Patients Abandon Diabetes Technology

Once significant dermatitis appears, repeatedly covering the affected skin with another sensor or infusion set is unlikely to solve the problem. The first goal is to identify what is happening while protecting continued access to diabetes technology when possible.

Mild irritation may improve with site rotation, gentler removal, and changes to the skin-preparation routine. More persistent, severe, recurrent, or spreading reactions warrant closer evaluation.

When allergic contact dermatitis is suspected, dermatology referral and patch testing may help identify a responsible allergen. The American Diabetes Association notes that patch testing can sometimes determine the cause of contact dermatitis and emphasizes identifying and eliminating tape allergens when possible.

Clinicians should also be cautious about recommending topical medications underneath a device without considering the specific product and device instructions. Treatments used for dermatitis may be appropriate in selected patients, but the medication, timing, application site, and potential effects on device adhesion need individualized consideration.

If reactions continue despite appropriate preventive measures, changing devices may become necessary. However, switching brands does not automatically eliminate risk because patients may encounter related allergens or new adhesive materials.

In selected patients with significant tape sensitivity, an implanted CGM may offer another option. Current diabetes guidance identifies implanted sensors as a potential strategy for some people who are sensitive to tape.

Above all, clinicians should treat skin tolerance as part of successful diabetes technology use. Skin irritation can contribute to device discontinuation, making dermatologic care part of supporting sustained technology use.

Conclusion

Skin problems related to CGM use should not be dismissed as a minor inconvenience. For some patients, itching, dermatitis, or repeated barrier damage can determine whether they continue using a CGM or insulin pump.

Prevention starts with healthy site selection, thoughtful rotation, gentle skin preparation, careful adhesive removal, and routine screening for early symptoms. Barrier films and supplemental adhesives may help selected patients, although they are not universally effective. When reactions persist or suggest allergy, dermatology evaluation and patch testing can help guide the next step.

Ultimately, protecting the skin helps protect access to the benefits of diabetes technology. A few questions about the device site during routine visits may prevent a manageable skin problem from becoming a reason to abandon CGM or pump therapy.

Frequently Asked Questions

What causes CGM skin irritation?

These skin reactions can result from friction, sweat, trapped moisture, repeated adhesive removal, or irritant exposure. Some patients instead develop allergic contact dermatitis to components associated with the device or adhesive.

Can a barrier film prevent CGM adhesive reactions?

It may help some patients, particularly when irritation rather than a true allergy is involved. However, barrier films do not prevent reactions in everyone. Device-specific instructions should be checked before placing barrier products beneath a sensor.

How can clinicians tell irritation from an adhesive allergy?

The appearance alone may not always provide a definitive answer. Timing, symptoms, rash distribution, previous reactions, and exposure history can offer clues. Persistent or recurrent suspected allergic contact dermatitis may require dermatology assessment and patch testing.

Should patients rotate CGM and insulin pump sites?

Yes. Appropriate site rotation gives previously used skin time to recover and helps reduce repeated local trauma. For insulin delivery, avoiding repeated use of the same area also helps reduce problems such as lipohypertrophy.

When should a patient with CGM-related skin irritation be referred to dermatology?

Consider referral when dermatitis is severe, persistent, recurrent, spreading beyond the contact area, or suspicious for allergic contact dermatitis. Patch testing may help identify specific allergens and guide future device selection or avoidance strategies.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.